1 tablet contains:
Active substance: tamoxifen citrate 30.4 mg, equivalent to 20 mg of tamoxifen content
Excipients: corn starch, lactose monohydrate, povidone, sodium starch glycolate, magnesium stearate, purified water
- Breast cancer in postmenopausal women;
- breast cancer in men after castration;
- kidney cancer;
- melanoma (containing estrogen receptors);
- ovarian cancer;
- prostate cancer with resistance to other drugs.
- increased sensitivity to tamoxifen.
From the digestive system: nausea, vomiting, increase in liver transaminases; in some cases – fatty liver, cholestasis, hepatitis
CNS: rare – depression, dizziness, headache, optic neuritis
From a sight organ: rare – retinopathy, keratopathy, cataract
From the hematopoietic system: rare – thrombocytopenia, leukopenia
From endocrine system: for women – endometrial hyperplasia, vaginal bleeding, hot flashes, weight gain; men – impotence, decreased libido
Cardio-vascular system: edema, thrombosis, phlebitis
Dermatologic reactions: alopecia, rash, itching,
Other: bone pain and lesions, fever
How to accept, acceptance rate and dosage
The mode set individually, depending on the evidence, the state of the patient and the applied scheme anticancer therapy.
Store at a temperature of 15-25 ° C.
In an application with anticoagulant coumarin derivatives increases the risk of increased anticoagulant effect; cytostatics – may increase the risk of thrombotic events
While the use of allopurinol may hepatotoxicity; with aminoglutethimide – decrease in the concentration of tamoxifen in plasma, apparently due to increasing its metabolism
In patients receiving tamoxifen may prolongation of neuromuscular blockade induced by atracurium.
With the simultaneous use of bromocriptine may increase the dopaminergic action of bromocriptine. In patients receiving tamoxifen, when warfarin is a risk of threatening clinical situations: possible prolongation of the prothrombin time, haematuria, hematoma
While the use of mitomycin C increases the risk of hemolytic-uremic syndrome.
Perhaps the decrease in the concentration of tamoxifen in plasma, which appears to be due to induction of CYP3A4 by rifampicin action.
Estrogen may reduce the therapeutic effect of tamoxifen.
Acute overdose of tamoxifen in humans has not been observed.
Symptoms: is to be expected that an overdose can cause amplification of the above adverse reactions.
Treatment: There is no specific antidote, treatment should be symptomatic